This consistency is particularly notable in the context of conditions such as polycythemia (linked with JAK2V617F or JAK2 exon 12 mutations) and thrombocytosis/myelofibrosis (associated with JAK2V617F and MPLW515L mutations) (Wernig et al., 2006), This implies that the persistent activation of the JAK-STAT signaling pathway plays a crucial role in the progression of PV, ET, and PMF. Here, JAK2 is linked to acquired polycythemia vera.